When did Halozyme Therapeutics report Q1 2025 earnings?

Halozyme Therapeutics (HALO) reported Q1 2025 earnings on May 6, 2025 after market close.

What were Halozyme Therapeutics's Q1 2025 revenue and EPS?

Halozyme Therapeutics reported revenue of $264.9M and eps of $1.11 for Q1 2025.

Did Halozyme Therapeutics beat estimates in Q1 2025?

Revenue missed the consensus estimate of $281.0M by $16.1M. EPS beat the consensus estimate of $0.95 by $0.16.

How did Halozyme Therapeutics's Q1 2025 results compare year-over-year?

Compared to the same quarter a year prior, revenue grew 35.2% from $195.9M a year earlier and eps grew 40.5% from $0.79.

Where can I find Halozyme Therapeutics's Q1 2025 SEC filings?

You can read the 10-Q periodic report (0001159036-25-000026) directly on SEC EDGAR. The filing index links above go to sec.gov.

Halozyme Therapeutics HALO Q1 2025 earnings

Reported May 6, 2025 · After market close

Revenue$264.9MMiss by $16.1M

EPS$1.11Beat by $0.16

Revenue estimate$281.0M

EPS estimate$0.95

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$402.3M

EPS estimate$1.82

Financials

Q1 2025

Income statement

See full

Revenue$264.9M+35.2%

Gross profit$216.5M+29.2%

Operating income$141.5M+48.1%

Net income$118.1M+53.7%

EPS (diluted)$0.93+55.0%

Balance sheet

See full

Cash & equivalents$176.3M+7.1%

Total debt$1.5B+0.3%

Total equity$482.3M+171%

Total assets$2.2B+19.3%

Cash flow

See full

Operating cash flow$154.2M+19.2%

CapEx$950.0K-73.2%

Free cash flow$153.3M+21.8%

Valuation & ratios

Valuation

as of 03/31/25

See full

Market cap$7.88B+52.6%

Enterprise value$9.24B+41.5%

P/E16.2×0.0×

P/S7.3×+1.3×

Profitability

See full

Gross margin83.4%+4.9pp

Operating margin55.1%+11.1pp

Net margin44.8%+7.8pp

FCF margin45.7%-3.4pp

Returns & leverage

See full

Return on equity147.1%-115pp

Debt / equity3.2×-5.4×

Current ratio8.4×+1.8×

Segments

By product

See full

Royalties$168.2M+39.5%

Proprietary product sales$36.3M+3.1%

Bulk rHuPH20 sales$27.0M+157%

Sales-based milestones$15.0M—

Device partnered product sales$14.7M+14.5%

By geography

See full

All other foreign$8.3M+250%

Versus estimates

Revenue

Q1 2026$376.7MBeat by $18.1M Q4 2025$451.8MBeat by $16.1M Q3 2025$354.3MMiss by $92.2M Q2 2025$325.7MMiss by $5.1M

Q1 2025$264.9MMiss by $16.1M

Q4 2024$298.0MBeat by $12.3M

Diluted EPS

Q1 2026$1.60Beat by $0.06 Q4 2025-$0.24Miss by $2.39 Q3 2025$1.72Beat by $0.09 Q2 2025$1.54Beat by $0.31

Q1 2025$1.11Beat by $0.16

Q4 2024$1.26Beat by $0.09

Ask the moment Halozyme Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Halozyme Therapeutics report Q1 2025 earnings?: Halozyme Therapeutics (HALO) reported Q1 2025 earnings on May 6, 2025 after market close.
What were Halozyme Therapeutics's Q1 2025 revenue and EPS?: Halozyme Therapeutics reported revenue of $264.9M and eps of $1.11 for Q1 2025.
Did Halozyme Therapeutics beat estimates in Q1 2025?: Revenue missed the consensus estimate of $281.0M by $16.1M. EPS beat the consensus estimate of $0.95 by $0.16.
How did Halozyme Therapeutics's Q1 2025 results compare year-over-year?: Compared to the same quarter a year prior, revenue grew 35.2% from $195.9M a year earlier and eps grew 40.5% from $0.79.
Where can I find Halozyme Therapeutics's Q1 2025 SEC filings?: You can read the 10-Q periodic report (0001159036-25-000026) directly on SEC EDGAR. The filing index links above go to sec.gov.